Status:
COMPLETED
Axillary Brachial Plexus Block Using 0.25% Bupivacaine Versus Using 0.19%Bupivacaine in Pediatrics
Lead Sponsor:
Cairo University
Conditions:
Acute Postoperative Pain
Motor Activity
Eligibility:
All Genders
4-14 years
Phase:
NA
Brief Summary
Postoperative pain is a common manifestation in orthopedic patients, mainly due to intraoperative tissue damage and inadequate intraoperative pain assessment and management .Axillary brachial plexus b...
Detailed Description
Patients meeting inclusion criteria will be randomly assigned to receive either: (Group A: n=30)will receive 0.25% bupivacaine plus 1 µg/kg dexmedetomidine . (Group B: n=30) will receive 0.19% bupiva...
Eligibility Criteria
Inclusion
- American society of Anesthesiologists (ASA )class I-II
- Duration of surgery less than 1 hour.
Exclusion
- Parent refusal.
- Prolonged procedure exceeding 1 hour.
- Patients with apparent infection at site of needle insertion.
- Patients with any coagulation disorder(Platelets ≤ 50,000 and/or international normalized ratio INR\> 1.5)
- Patients with known neuropathy or brachial plexus injury.
- Patients with any cardiac, hepatic, renal failure.
- Patient with known sensitivity to local anesthetic drugs.
Key Trial Info
Start Date :
May 29 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 10 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05386095
Start Date
May 29 2022
End Date
November 10 2022
Last Update
March 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kasr Alainy Hospitals
Giza, Cairo Governorate, Egypt, 11562